Radiopharm Theranostics Limited (RADX)

2.08USD -3.48% (-0.07)

Over 6M: -57.9%

Style
Area Line Line with markers Steps Candles Hollow candles Bars

Candles and bars need the day’s open, high and low, and need room to be drawn in: past about a year of trading a body is thinner than a hairline, so those three offer the longest window that fits instead.

2 3 4 5
Mar Apr May Jun Jul Aug Sep

Financials Annual

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
FY23 — Revenue: 292.4K FY23 — Operating Income: -34.5M FY23 — Operating Cash Flow: -23.2M FY24 — Revenue: 299.2K FY24 — Operating Income: -47.2M FY24 — Operating Cash Flow: -23M FY25 — Revenue: 3.6M FY25 — Operating Income: -38.2M FY25 — Operating Cash Flow: -36.6M -45M -30M -15M 0 15M
FY23 FY24 FY25
Revenue Operating Income Operating Cash Flow

How it scores

For a valuation multiple, the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

0.6
SBC / sales 52.2%
OE margin -1060.7%
Oper. margin -1050.6%
ROIC -219.2%
Accruals -2.0%
Asset turnover 0.042×
EBITDA margin -979.2%
FCF margin -1008.6%
OCF margin -1008.6%
Profit margin -1055.3%
ROA -44.3%
ROCE -53.4%
ROE -89.4%
Capex / sales —
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.8
EV/Sales 1345.8×
EV/OE -126.9×
EV/GP 124503.0×
FCF yield -0.74%
P/B 114.7×
P/C 168.9×
Div. yield —
EV/EBIT —
Fwd P/E —
P/E —
PEG —

2 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.0
ND/EBITDA 0.006
Interest cover -584.6×
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 2.7×
Cash runway 0.79 yr
F-score 4.5 pts
Cash / Debt —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

10.0
Sales/sh Y/Y +125.2%
Shares change +439.1%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —

3 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.